Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study.

Expert review of anticancer therapy - 1 Mar 2026

Su Bosheng, Xie Yuwei, Zhou Yingnan, Shi Fumin, Wang Jia, Xu Long

Abstract excerpt

BACKGROUND: Patients with advanced EGFR-mutant NSCLC and high PD-L1 expression (TPS ≥50%) typically respond poorly to EGFR-TKI monotherapy. We compared EGFR-TKI plus chemotherapy versus TKI alone in this population. RESEARCH DESIGN AND METHODS: This retrospective study included 212 patients receiving first-line osimertinib with chemotherapy (n = 98) or as monotherapy (n = 114). Primary endpoint was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to B7-H1 Antigen

Share to Indoles

Share to Progression-Free Survival

Share to Pyrimidines

Share to Survival Rate

Source

Identifiers

PMID: 41247784
DOI: 10.1080/14737140.2025.2591286

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study.PMID 41247784Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudySemantic proximity Read ↗

Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.Semantic proximity Read ↗

Real-Life Use of First-Generation EGFR-TKI with Chemotherapy in EGFR-sensitive Mutations in Non-Small-Cell Lung Cancer: A Single-Center Analysis and Meta-AnalysisSemantic proximity Read ↗

First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.Semantic proximity Read ↗

Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity Read ↗

Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.Semantic proximity Read ↗

Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisSemantic proximity Read ↗

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.